KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E Adjustments
Ratios

TherapeuticsMD (TXMD) Accumulated Depreciation & Amortization: 2011-2023

Historic Accumulated Depreciation & Amortization for TherapeuticsMD (TXMD) over the last 13 years, with Sep 2023 value amounting to $2.5 million.

  • TherapeuticsMD's Accumulated Depreciation & Amortization fell 16.46% to $2.5 million in Q3 2023 from the same period last year, while for Sep 2023 it was $9.9 million, marking a year-over-year decrease of 5.58%. This contributed to the annual value of $2.4 million for FY2022, which is 24.05% up from last year.
  • TherapeuticsMD's Accumulated Depreciation & Amortization amounted to $2.5 million in Q3 2023, which was up 0.76% from $2.5 million recorded in Q2 2023.
  • In the past 5 years, TherapeuticsMD's Accumulated Depreciation & Amortization ranged from a high of $3.0 million in Q3 2022 and a low of $106,938 during Q2 2019.
  • Its 3-year average for Accumulated Depreciation & Amortization is $2.4 million, with a median of $2.5 million in 2023.
  • In the last 5 years, TherapeuticsMD's Accumulated Depreciation & Amortization plummeted by 76.31% in 2019 and then spiked by 716.81% in 2021.
  • TherapeuticsMD's Accumulated Depreciation & Amortization (Quarterly) stood at $968,824 in 2019, then spiked by 79.70% to $1.7 million in 2020, then grew by 13.21% to $2.0 million in 2021, then rose by 24.05% to $2.4 million in 2022, then decreased by 16.46% to $2.5 million in 2023.
  • Its Accumulated Depreciation & Amortization stands at $2.5 million for Q3 2023, versus $2.5 million for Q2 2023 and $2.5 million for Q1 2023.